Center for Scientific Review; Notice of Closed Meetings, 35372 [2016-12898]
Download as PDF
<![CDATA[
35372
Federal Register / Vol. 81, No. 106 / Thursday, June 2, 2016 / Notices
Dated: May 27, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–12998 Filed 6–1–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c) (6), Title 5
U.S.C., as amended. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR13–280:
Program Project: Mechanisms of Membrane
Fusion.
Date: June 14, 2016.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: David R Jollie, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4150,
MSC 7806, Bethesda, MD 20892, (301)-435–
1722, jollieda@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Brain Disorders and
Clinical Neuroscience Integrated Review
Group; Clinical Neuroplasticity and
Neurotransmitters Study Section.
Date: June 16–17, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Renaissance Mayflower Hotel, 1127
Connecticut Avenue NW., Washington, DC
20036.
Contact Person: Suzan Nadi, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5217B,
MSC 7846, Bethesda, MD 20892, 301–435–
1259, nadis@csr.nih.gov.
VerDate Sep<11>2014
20:01 Jun 01, 2016
Jkt 238001
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Cardiovascular and
Respiratory Sciences Integrated Review
Group; Myocardial Ischemia and Metabolism
Study Section.
Date: June 23–24, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814
Contact Person: Kimm Hamann, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4118A,
MSC 7814, Bethesda, MD 20892, 301–435–
5575, hamannkj@csr.nih.gov.
Name of Committee: Brain Disorders and
Clinical Neuroscience Integrated Review
Group; Developmental Brain Disorders Study
Section.
Date: June 23–24, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Melrose Hotel, 2430 Pennsylvania
Avenue NW., Washington, DC 20037.
Contact Person: Pat Manos, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5200,
MSC 7846, Bethesda, MD 20892, 301–408–
9866, manospa@csr.nih.gov.
Name of Committee: Oncology 2—
Translational Clinical Integrated Review
Group; Chemo/Dietary Prevention Study
Section.
Date: June 23–24, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Warwick Seattle Hotel, 401 Lenora
Street, Seattle, WA 98121.
Contact Person: Svetlana Kotliarova, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6214,
Bethesda, MD 20892, 301–594–7945,
kotliars@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Drug
Discovery and Mechanisms of Antimicrobial
Resistance.
Date: June 23, 2016.
Time: 1:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: American Inn of Bethesda, 8130
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: John C Pugh, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1206,
MSC 7808, Bethesda, MD 20892, (301) 435–
2398, pughjohn@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846-93.878, 93.892, 93.893, National
Institutes of Health, HHS)
PO 00000
Frm 00080
Fmt 4703
Sfmt 4703
Dated: May 26, 2016.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–12898 Filed 6–1–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health.
Notice.
AGENCY:
ACTION:
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 209 and 37 CFR part 404 to
achieve expeditious commercialization
of results of federally-funded research
and development.
FOR FURTHER INFORMATION CONTACT:
Licensing information may be obtained
by emailing the indicated licensing
contact at the National Heart, Lung, and
Blood, Office of Technology Transfer
and Development Office of Technology
Transfer, 31 Center Drive Room 4A29,
MSC2479, Bethesda, MD 20892–2479;
telephone: 301–402–5579. A signed
Confidential Disclosure Agreement may
be required to receive any unpublished
information.
SUPPLEMENTARY INFORMATION:
Technology description follows.
SUMMARY:
Albumin Binding Immunomodulatory
Compositions
The invention relates to molecules
wherein Evan’s Blue dye is chemically
conjugated to CpG Oligonucleotides that
elicit anti-tumoral or infection fighting
immunity. Evans Blue, a symmetric azo
dye, has high binding affinity to
albumin. Albumin binding ability of
Evans blue is utilized with CpGs and
tumor-specific antigens, in order to
leverage endogenous albumin that
increases the safety and the potency of
molecular vaccines. As such, the
molecular entities provided here enable
efficient delivery and prolonged
retention in lymph nodes and reduce
systemic toxicity of Evans Blue and
enhanced the therapeutic potency of
molecular vaccines.
Potential Commercial Applications:
• Cancer therapeutics
• Infectious disease therapeutics
• Lymph node specificity
• Higher stability/Lower toxicity
Development Stage:
• Early stage
E:\FR\FM\02JNN1.SGM
02JNN1
]]>Agencies
[Federal Register Volume 81, Number 106 (Thursday, June 2, 2016)]
[Notices]
[Page 35372]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-12898]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c) (6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; PAR13-280: Program Project: Mechanisms of Membrane Fusion.
Date: June 14, 2016.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Virtual Meeting).
Contact Person: David R Jollie, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4150, MSC 7806, Bethesda, MD
20892, (301)-435-1722, jollieda@csr.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: Brain Disorders and Clinical Neuroscience
Integrated Review Group; Clinical Neuroplasticity and
Neurotransmitters Study Section.
Date: June 16-17, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Renaissance Mayflower Hotel, 1127 Connecticut Avenue NW.,
Washington, DC 20036.
Contact Person: Suzan Nadi, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 5217B, MSC 7846, Bethesda, MD 20892, 301-435-
1259, nadis@csr.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: Cardiovascular and Respiratory Sciences
Integrated Review Group; Myocardial Ischemia and Metabolism Study
Section.
Date: June 23-24, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400
Wisconsin Avenue, Bethesda, MD 20814
Contact Person: Kimm Hamann, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 4118A, MSC 7814, Bethesda, MD 20892, 301-435-
5575, hamannkj@csr.nih.gov.
Name of Committee: Brain Disorders and Clinical Neuroscience
Integrated Review Group; Developmental Brain Disorders Study
Section.
Date: June 23-24, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Melrose Hotel, 2430 Pennsylvania Avenue NW., Washington,
DC 20037.
Contact Person: Pat Manos, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 5200, MSC 7846, Bethesda, MD 20892, 301-408-
9866, manospa@csr.nih.gov.
Name of Committee: Oncology 2--Translational Clinical Integrated
Review Group; Chemo/Dietary Prevention Study Section.
Date: June 23-24, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Warwick Seattle Hotel, 401 Lenora Street, Seattle, WA
98121.
Contact Person: Svetlana Kotliarova, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6214, Bethesda, MD 20892, 301-
594-7945, kotliars@mail.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Drug Discovery and Mechanisms of Antimicrobial Resistance.
Date: June 23, 2016.
Time: 1:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: American Inn of Bethesda, 8130 Wisconsin Avenue,
Bethesda, MD 20814.
Contact Person: John C Pugh, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 1206, MSC 7808, Bethesda, MD 20892, (301) 435-
2398, pughjohn@csr.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: May 26, 2016.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-12898 Filed 6-1-16; 8:45 am]
BILLING CODE 4140-01-P
